KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Operations (2018 - 2025)

Moderna (MRNA) has disclosed Cash from Operations for 8 consecutive years, with 930000000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 12.73% to 930000000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1873000000.0 through Dec 2025, up 37.65% year-over-year, with the annual reading at 1873000000.0 for FY2025, 37.65% up from the prior year.
  • Cash from Operations for Q4 2025 was 930000000.0 at Moderna, up from 847000000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 4063000000.0 in Q2 2021, with the low at 1600000000.0 in Q3 2023.
  • Average Cash from Operations over 5 years is 530300000.0, with a median of 278000000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 17029.17% in 2021, then crashed 734.92% in 2023.
  • Over 5 years, Cash from Operations stood at 3310000000.0 in 2021, then crashed by 49.79% to 1662000000.0 in 2022, then crashed by 62.58% to 622000000.0 in 2023, then surged by 32.64% to 825000000.0 in 2024, then increased by 12.73% to 930000000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 930000000.0, 847000000.0, and 919000000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.